



Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1632

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/622,452
		Filing Date	10/31/2000
		First Named Inventor	David B. Weiner
		Group Art Unit	1632
		Examiner Name	Anne Marie Sabrina Wehbe
Total Number of Pages in This Submission		Attorney Docket Number	UPAP-0404

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Mark DeLuca, Reg. No. 33,229 Cozen O'Connor, PC
Signature	
Date	11/01/02

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	Mark DeLuca	
Signature		Date
		11/01/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

NOV 15 2002

TECH CENTER 1600/2900



DOCKET NO.: UPAP-0404 (K-1765)

PATENT

#113
Dec
11/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David B. Weiner, Jong J. Kim and Jeong-Im Sin

Serial No.: 09/622,452

Group Art Unit: 1632

Filed: October 31, 2000

Examiner: **Anne Marie Sabrina Wehbe**

For: **VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME**

I, **Mark DeLuca**, Registration No. 33,229 certify that this correspondence is being deposited with the U.S. Patent Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on

Washington, D.C. 20510-0000
Nov 1, 2002
uncl

Mark DeLuca Reg. No. 33,229

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

NOV 15 2002

Dear Sir:

REPLY

TECH CENTER 1600/2900

This reply is being filed in response to the Official Action dated October 2, 2002 for the above-identified patent application. Please amend the application as follows.

In the Claims:

Please cancel claims 5, 8, 16, 19, 23-32 and 37-39 without prejudice and amend claims 9-11, 20-22 and 33 as follows.

The plasmid of claim 1 wherein said immunogen is herpes simplex antigen HSV2gD.

Feb C1 BT